Celon Pharma (FRA:8RP) ROCE % : 44.74% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Celon Pharma's annualized ROCE % for the quarter that ended in Sep. 2024 was 44.74%.

Celon Pharma ROCE % Historical Data

The historical data trend for Celon Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma ROCE % Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

1.44

-1.00

-2.67

-6.20

-3.43

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-6.04	-5.73	-10.30	-8.03	44.74

Celon Pharma ROCE % Calculation

Celon Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.288	/	( ( (159.27 - 28.853)	+	(141.069 - 21.393) )	/ 2 )
	=	-4.288	/	( (130.417	+	119.676)	/ 2 )
	=	-4.288	/	125.0465
	=	-3.43 %

Celon Pharma's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	57.868	/	( ( (142.809 - 19.65)	+	(153.42 - 17.908) )	/ 2 )
	=	57.868	/	( ( 123.159	+	135.512 )	/ 2 )
	=	57.868	/	129.3355
	=	44.74 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Celon Pharma (FRA:8RP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Celon Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Celon Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLN:Poland

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines